ATLANTA, GA, Sept. 10, 2025 (GLOBE NEWSWIRE) -- Geotab Inc. (“Geotab”), a global leader in connected vehicle solutions and asset management, today announced a significant research investment of up to ...

Srinivas Kodali, an independent researcher, has filed a complaint with the Chief Electoral Officer of Telangana alleging that the Election Commission has unlawfully shared photographs and names of ...

Hydrates, Flow Assurance & Phase Equilibria Research Group, Institute of GeoEnergy Engineering, Heriot-Watt University, Edinburgh EH14 4AS, U.K.

Judge Amit P. Mehta said the company must hand over some of its search data to rivals, but did not force other big changes the U.S. wanted. By David McCabe David McCabe has covered the Google search ...

Crypto inflows fell to $223 million after hitting $883 million midweek, reversing sharply due to hawkish FOMC signals and strong US economic data. Bitcoin saw $404 million in outflows, while Ethereum, ...

(UroToday.com) The 2025 SNMMI annual meeting featured a prostate cancer and dosimetry session and a presentation by Dr. Sabina Dizdarevic discussing eight-year follow-up of patient outcomes and bone ...

Shares of Circle (CRCL) began trading on the New York Stock Exchange (NYSE) on Thursday, opening at $69 a share in early trading. The stock at one point surged to as much as $100, more than 200% above ...

The REASSURE trial confirmed the strong safety profile of Ra-223 in metastatic castration-resistant prostate cancer over a median follow-up of 17 months. Adverse events occurred in 50% of patients, ...

XOFIGO® (radium-223 dichloride) in combination with enzalutamide significantly increased radiological progression-free survival (rPFS) for patients with metastatic castration-resistant prostate cancer ...

New data from the Phase III PEACE III trial showed that XOFIGO ® (radium-223 dichloride) in combination with enzalutamide significantly improved prostate-specific antigen (PSA) response rates (≥90% at ...